BMO Capital Upgrades Blueprint Medicines (BPMC) to Outperform

March 17, 2020 6:03 AM EDT Send to a Friend
BMO Capital analyst George Farmer upgraded Blueprint Medicines (NASDAQ: BPMC) from Market Perform to Outperform with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login